Revolutionary Gene Therapy Treatment Receives FDA Approval for Rare Disease
Sickle cell disease patients now have access to the world’s first commercially approved gene therapy that directly edits their DNA. Lyfgenia, developed by bluebird bio, received FDA approval last week after demonstrating remarkable success in clinical trials where 95% of…
